The tender offer, which expires Dec. 10, is the latest step by Sanofi as it tries to buy Genzyme to gain a significant toehold in the lucrative biopharmaceutical industry. Big drug makers have looked to companies like Genzyme because their drugs, which often treat rare diseases, are less susceptible to price competition from generic rivals.